Genzyme Co-Pay Assistance Program
The Genzyme Co-Pay Assistance Program helps eligible individuals in the United States who are prescribed treatment with Cerezyme pay for their eligible out-of-pocket drug and infusion-related expenses, including co-pays, co-insurance and deductibles, regardless of financial status.
Once enrolled in Genzyme's Co-Pay Assistance Program, Genzyme will cover 100% of your eligible out-of-pocket Cerezyme drug and infusion-related costs up to the program maximum.
Once approved for assistance, your healthcare provider will be provided with information about your enrollment in this program along with directions on how to submit a claim to the Genzyme Co-Pay Assistance Program.
Who is eligible for the Genzyme Co-Pay Assistance Program?
Regardless of financial status, the program is open to individuals who are:
- U.S. citizens or legal residents who have primary commercial insurance
- Prescribed treatment with Cerezyme
You are NOT eligible if you:
- Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
- Medicare Advantage Plans
(Example: FreedomBlue offered through Blue Cross Blue Shield)
- Veterans Affairs, Department of Defense or TRICARE
- Federal Employee Plan (FEP)
- High Risk Pool or Pre-existing Condition Insurance Plan (PCIP)
- In accordance with State law, the Program does not reimburse infusion-related charges for patients residing in Massachusetts, Michigan, Minnesota and Rhode Island.
Genzyme reserves the right to make eligibility determinations, to set program benefit maximums, to monitor participation, and to modify or discontinue the program at any time. This program assists patients with their out-of-pocket drug and infusion-related costs of Cerezyme only, not the cost of medical evaluations/appointments, testing, or other related services.
How to get started:
You complete the program application
Simply complete the online application available here.
Helpful information to have on hand when you apply:
- Your treating Physician's contact information
- Your health insurance card
You can also call your Genzyme Case Manager directly to learn more about the program and application process at 1-800-745-4447, Option 3
Your eligibility is verified
Your application will be reviewed for eligibility.
If you are eligible, you will be automatically enrolled in the program. Enrollment in the program is subject to confirmation of eligibility.
Once approved, you will receive a confirmation letter and an enrollment card within 7-10 days. Contact your Genzyme Case Manager if you do not receive this confirmation.
Your doctor or specialty pharmacy will receive a phone call with instructions on how to submit claims for reimbursement through the program.
Your enrollment in the program is effective from the date of approval through the end of the calendar year (calendar year is January 1 through December 31).
If you are currently enrolled in our Co-Pay Assistance Program you will be automatically enrolled in the program for the next calendar year (January 1 through December 31) unless you decide to opt out of the program or your insurance coverage changes.
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- anemia (low red blood cell count)
- thrombocytopenia (low blood platelet count)
- bone disease
- hepatomegaly or splenomegaly (enlarged liver or spleen)
Important Safety Information
Approximately 15% of patients have developed immune responses (antibodies). These patients have a higher risk of an allergic reaction (hypersensitivity). Use Cerezyme® (imiglucerase for injection) carefully if you have had an allergic reaction to the product in the past. Symptoms suggestive of allergic reaction happened in 6.6% of patients, and include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure.
Side effects related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Cerezyme is available by prescription only. For more information, consult your physician.
Please see Full Prescribing Information (PDF).